Table 2.
Clinical characteristics of patients with gynecological malignancies in our patient cohort undergoing assessment of their attitude towards vaccination.
| Characteristics | All patients | Registered for vaccination | Postponing vaccination | Refusing vaccination |
|---|---|---|---|---|
| In total |
19 |
7 |
11 |
1 |
| Age | ||||
| median/mean (y) | 56/56.6 | 56/58.9 | 54/54.45 | 64 |
| range (y) |
34–78 |
52–78 |
34–78 |
|
| Type of carcinoma | ||||
| ovarian (%) | 13 (68.4) | 6 (46.2) | 6 (46.2) | 1 (5.3) |
| simulate ovarian + endometrium (%) | 2(10.5) | 1 (50) | 1 (50) | |
| endometrium (%) | 2 (10.5) | 0 | 2 (100) | |
| cervical (%) |
2 (10.5) |
0 |
2 (100) |
|
| FIGO stage of disease | ||||
| I/II | 1 (5.3) | 0 | 1 | 0 |
| III/IV (%) |
18 (94.7) |
7 (38.9) |
10 (55.6) |
1 (5.6) |
| Therapy modality | ||||
| adjuvant therapy (%) | 4 (21.1) | 3 (75.0) | 1 (25.0) | 0 |
| metastatic therapy (%) | 7 (36.8) | 2 (28.6) | 5 (62.5) | 1 (12.5) |
| maintenance therapy (%) | 5 (26.3) | 2 (40.0) | 3 (60.0) | 0 |
| recurrent therapy (%) |
3 (15.8) |
0 |
2 (100) |
0 |
| Oncological therapy | ||||
| chemotherapy (%) | 12 (63.2) | 4 (3.3) | 7 (58.3) | 1 (8.3) |
| targeted therapy (%) | 5 (26.3) | 3 (60.0) | 2 (40.0) | 0 |
| immunotherapy ± chemotherapy (%) | 2 (10.5) | 0 | 2 (100) | 0 |